Professor Duncan McHale
Vice President Global Exploratory Development
Duncan is the Head of Exploratory Development for UCB.This group is responsible for the early testing of novel therapies in humans in collaboration with the New Medicines Therapeutic area colleagues.
He is the ABPI (Association of the British Pharmaceutical Industry) Stratified Medicines Lead and a member of multiple MRC panels. He has a visiting Professorship at the Wolfson Personalized Medicine Unit at Liverpool University. He joined UCB in September 2011, prior to that he was the head of Translational Science at AstraZeneca and before that the European Head of Translational Molecular Medicine at Pfizer.
Duncan is a clinical geneticist and trained in General Adult Medicine at the University of Newcastle upon Tyne and then completed a PhD in the genetics of Cerebral Palsy at Leeds University. He has spent 13 years in Industry focusing on pharmacogenetics, early development and personalised medicine and is the author of the ICH E15 and E16 guidelines focusing on biomarker development and qualification.